Thus, because only KRAS fragments in plasma were validated with ddPCR, we hypothesized that KRAS mutant fragments in plasma, as well as the concentration of cfDNA, would be correlated with tumor burden in the liver. The gene discussed is KRAS; the disease is neoplasm.